S1PR4-dependent effects of Etrasimod on primary human myeloid immune cell activation
Taken together, our data show that S1PR4 takes on an essential role in the regulation of various immunological functions, and that Etrasimod can act as a superagonist/functional antagonist of S1PR4.
Authors
- Ewgenij Proschak (ORCID: https://orcid.org/0000-0003-1961-1859)
- Aissa Miriam Röhrig (ORCID: https://orcid.org/0000-0003-0472-0622)
- Megan A. Palmer (ORCID: https://orcid.org/0000-0002-5188-792X)
- Dariusz Stepniak
- Simeon Ramsey
- Jan Heering (ORCID: https://orcid.org/0000-0002-4922-1993)
- Andreas Weigert (ORCID: https://orcid.org/0000-0002-7529-1952)
- Anette Brockmann
- Bernhard Brüne (ORCID: https://orcid.org/0000-0001-8237-2841)
- Mohammed A.F. Elewa (ORCID: https://orcid.org/0000-0002-4633-5274)
- Blerina Aliraj (ORCID: https://orcid.org/0009-0003-1553-7687)
- Fiona Sailer
Institutions
- Goethe University Frankfurt (DE)
- Kafrelsheikh University (EG)
- Pfizer (United States) (US)
- Fraunhofer Institute for Translational Medicine and Pharmacology (DE)
- Arena Pharmaceuticals (United States) (US)
- University Hospital Frankfurt (DE)
- Frankfurt Cancer Institute (DE)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-04-24
- DOI
- https://doi.org/10.3389/fphar.2025.1590816
- Primary Topic
- Research on Leishmaniasis Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- Deutsche Forschungsgemeinschaft
- Fraunhofer-Gesellschaft